1įurther, PSA 50% (decrease ≥50% from baseline) response rates were 93% (77/83) in the combination arm, compared with 68% (54/79) for enzalutamide alone ( P <. Median radiographic PFS was 16 months with the combination therapy compared with 12 months for enzalutamide alone (HR, 0.67 95% CI, 0.44-1.01). Vincent’s Hospital in Sydney, Australia.ĭata from the study showed a median PSA-PFS of 13 months with the combination therapy compared with 7.8 months with enzalutamide alone (HR, 0.43 95% CI, 0.29-0.63 P =. Emmett is the director of theranostics and nuclear medicine at St. It provides strong evidence for an enhanced anti-cancer effect with the combination of enzalutamide and 177Lu-PSMA-617 based on the primary end point, PSA-PFS,” said Louise Emmett, MD, FRACP, during an oral presentation of the findings at the ESMO meeting. “This is the first randomized trial combining an androgen receptor signaling inhibitor, enzalutamide, with 177Lu-PSMA-617. Interim results from the phase 2 ENZA-p study (NCT04419402) show that adding 177Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) significantly enhances prostate-specific antigen progression-free survival (PSA-PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to findings presented at the European Society of Medical Oncology (ESMO) Congress, Madrid, Spain.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |